作者
Scott Kopetz,Axel Grothey,Rona Yaeger,Eric Van Cutsem,Jayesh Desai,Takayuki Yoshino,Harpreet Wasan,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod K. Guren,Hendrik‐Tobias Arkenau,Pilar García‐Alfonso,Per Pfeiffer,Sergey Orlov,Sara Lonardi,Elena Élez,Tae-Won Kim,Jan H.M. Schellens,Christina Guo,Asha Krishnan,Jeroen Dekervel,Van K. Morris,Aitana Calvo,Line Schmidt Tarpgaard,Michael Braun,Ashwin Gollerkeri,Christopher Hunt Keir,Kati Maharry,Michael D. Pickard,Janna Christy‐Bittel,Lisa Anderson,Victor Sandor,Josep Tabernero
摘要
Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling.
迷路的问儿
有人
嗯哼
藤椒辣鱼
jyy
MchemG
归尘
Henry
oydent
楚楚
俞无声
Cochrane
龍一
若雨凌风
VDC
眯眯眼的衬衫
冷艳的立果
YifanWang
Yifan2024
嘻哈hang
皖公网安备34019202002308
